Crystalline forms of pyrazolopyrimidine ester compounds and methods for preparing same
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- SHANGHAI MAIUS PHARM CO LTD
- Filing Date
- 2023-08-09
- Publication Date
- 2026-06-15
AI Technical Summary
The amorphous pyrazolopyrimidine ester compound used as a BTK inhibitor prodrug exhibits poor stability under normal storage conditions, decomposing significantly under heat and humidity, making it difficult to handle and store.
Development of a stable crystalline form (Form II) characterized by specific X-ray diffraction peaks and infrared absorption bands, allowing for long-term storage without special environmental controls.
The crystalline form II provides enhanced stability, enabling long-term storage and processing without temperature, light, or humidity concerns, with improved purity and reproducibility.
Smart Images

Figure 2024037396000001 
Figure 2024037396000002 
Figure 2024037396000003